Predicting recovery from hep C

The standard of care for HCV infection is a combination of the following drugs:

- a long-lasting form of interferon called pegylated interferon (Pegasys or Pegetron)
- the nucleoside analogue ribavirin

These therapies have side effects and usually have to be taken for one year. After that time, an additional six months of observation is necessary before doctors can be sure that HCV is cured. The rate of recovery from HCV in co-infected people is poor compared to HCV mono-infected people. Researchers in Bonn and Köln, Germany, have been trying to find ways to assess the early virologic responses to HCV therapy to see if they can predict who will recover in the long term. In this way, patients may be spared unnecessary exposure to interferon and ribavirin and their side effects.

Study details

Researchers reviewed their clinic databases and selected certain patients for data-analysis, as follows:

- All patients had received standard doses of pegylated interferon once weekly.
- Their dose of ribavirin was adjusted for their weight (this is roughly equivalent to about 1,200 mg/day).
- Patients with the easier-to-treat genotypes 2 and 3 were given between 24 and 48 weeks of therapy. Patients with the more difficult genotypes 1 and 4 were given 48 weeks of therapy. After therapy, all patients were monitored for 24 more weeks. At the end of this time, blood tests were done to detect HCV.

There were a total of 227 co-infected patients available for analysis with the following average profile:

- 27% females, 73% males
- 60% were taking HAART
- age – 41 years
- CD4+ count – 531 cells
- HIV viral load – 12,000 copies

The distribution of HCV genotypes was as follows:

- genotype 1: 56%
- genotype 2: 6%
- genotype 3: 31%
- genotype 4: 7%

Results

The overall virologic results of participants were as follows:

- recovery: 41%
- no response: 40%
- relapse: 11%
- no detectable HCV but liver enzymes were strangely elevated, suggesting that HCV was still present deep within the liver: 8%

Predicting recovery

Factors that suggested patients were likely to recover were as follows:
• infection with genotype 2 or 3
• having a rapid HCV virologic response (RVR) – this means having HCV that becomes undetectable after four weeks of treatment
• having an early HCV virologic response (EVR) – having viral load decrease by at least 2 logs after 12 weeks of treatment

The following factors were useful in predicting an EVR:

• having HCV genotype 2 or 3
• having an RVR
• not using HAART while receiving treatment for hepatitis C

The study team offered two reasons why, in this preliminary analysis, not using HAART appeared to be associated with an EVR:

• People not taking HAART would be more likely to have a strong immune system (high CD4 counts and/or stabilized HIV infection) and this may be a factor associated with an EVR.
• Drug interactions between HAART and hep C treatment may be a factor associated with an EVR. People not taking HAART would not experience such interactions.

More research is needed to understand the potential relationship between HAART and an EVR.

Because retrospective studies such as this are based on looking back, the researchers may have missed collecting and analyzing important data. Therefore, biased interpretation of their results cannot be ruled out. In such cases, prospective studies are needed to confirm the conclusions reached by the German team.

**REFERENCE:**

Disclaimer

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question.

CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.

CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders.

Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs.

Permission to Reproduce

This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at 1.800.263.1638.

© CATIE

Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada.

Available online at: